Neuren Pharmaceuticals Limited (NURPF)
USD 7.63
(10.58%)
USD 7.63
(10.58%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 205.19 Million AUD | 1310.81% |
| 2022 | 14.54 Million AUD | 356.04% |
| 2021 | 3.18 Million AUD | 348.52% |
| 2020 | 711 Thousand AUD | 44.81% |
| 2019 | 491 Thousand AUD | -96.35% |
| 2018 | 13.46 Million AUD | 2335.26% |
| 2017 | 553 Thousand AUD | -81.99% |
| 2016 | 3.07 Million AUD | 93.94% |
| 2015 | 1.58 Million AUD | 122.34% |
| 2014 | -7.08 Million AUD | -83.6% |
| 2013 | -3.85 Million AUD | 0.0% |
| 2012 | - AUD | 0.0% |
| 2011 | - AUD | -100.0% |
| 2010 | 4.64 Million AUD | -7.1% |
| 2009 | 5 Million AUD | 119.98% |
| 2008 | 2.27 Million AUD | 140.89% |
| 2007 | 944.16 Thousand AUD | 445.86% |
| 2006 | 172.96 Thousand AUD | -59.74% |
| 2005 | 429.66 Thousand AUD | -69.3% |
| 2004 | 1.39 Million AUD | -50.64% |
| 2003 | 2.83 Million AUD | 33.68% |
| 2002 | 2.12 Million AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 3.21 Million AUD | -98.0% |
| 2024 Q2 | 3.21 Million AUD | 0.0% |
| 2023 Q1 | 25.91 Million AUD | 78.17% |
| 2023 Q4 | 161.16 Million AUD | 110.19% |
| 2023 FY | 205.17 Million AUD | 1310.81% |
| 2023 Q3 | 76.67 Million AUD | 33.63% |
| 2023 Q2 | 57.38 Million AUD | 121.39% |
| 2022 Q2 | -4000.00 AUD | 99.83% |
| 2022 Q1 | -2.3 Million AUD | -244.56% |
| 2022 Q3 | 3.65 Million AUD | 91537.5% |
| 2022 Q4 | 14.54 Million AUD | 297.73% |
| 2022 FY | 14.54 Million AUD | 356.04% |
| 2021 Q3 | 320.5 Thousand AUD | 8112.5% |
| 2021 FY | 3.18 Million AUD | 348.52% |
| 2021 Q4 | 1.59 Million AUD | 397.5% |
| 2021 Q1 | -3.48 Million AUD | -1078.9% |
| 2021 Q2 | -4000.00 AUD | 99.89% |
| 2020 Q2 | -3000.00 AUD | 99.86% |
| 2020 Q4 | 355.5 Thousand AUD | 125.3% |
| 2020 Q3 | -1.4 Million AUD | -46733.33% |
| 2020 Q1 | -2.11 Million AUD | -959.23% |
| 2020 FY | 711 Thousand AUD | 44.81% |
| 2019 FY | 491 Thousand AUD | -96.35% |
| 2019 Q2 | -3000.00 AUD | 99.91% |
| 2019 Q3 | -1.21 Million AUD | -40300.0% |
| 2019 Q1 | -3.46 Million AUD | -165.89% |
| 2019 Q4 | 246.5 Thousand AUD | 120.34% |
| 2018 Q3 | 5.26 Million AUD | 498.6% |
| 2018 Q1 | -1.32 Million AUD | -8.99% |
| 2018 Q4 | 5.26 Million AUD | 0.0% |
| 2018 FY | 13.46 Million AUD | 2335.26% |
| 2018 Q2 | -1.32 Million AUD | 0.0% |
| 2017 Q1 | -1.04 Million AUD | 43.19% |
| 2017 FY | 553 Thousand AUD | -81.99% |
| 2017 Q3 | -1.21 Million AUD | -16.48% |
| 2017 Q2 | -1.04 Million AUD | 0.0% |
| 2017 Q4 | -1.21 Million AUD | 0.0% |
| 2016 Q2 | -3.25 Million AUD | 0.0% |
| 2016 FY | 3.07 Million AUD | 93.94% |
| 2016 Q1 | -3.25 Million AUD | 13.89% |
| 2016 Q4 | -1.83 Million AUD | 0.0% |
| 2016 Q3 | -1.83 Million AUD | 43.75% |
| 2015 FY | 1.58 Million AUD | 122.34% |
| 2015 Q4 | -3.78 Million AUD | 0.0% |
| 2015 Q1 | -2.44 Million AUD | -18.54% |
| 2015 Q2 | -2.44 Million AUD | 0.0% |
| 2015 Q3 | -3.78 Million AUD | -54.42% |
| 2014 Q3 | -2.06 Million AUD | -39.84% |
| 2014 Q1 | -1.47 Million AUD | -8.8% |
| 2014 Q4 | -2.06 Million AUD | 0.0% |
| 2014 FY | -7.08 Million AUD | -83.6% |
| 2014 Q2 | -1.47 Million AUD | 0.0% |
| 2013 Q3 | -1.35 Million AUD | -137.33% |
| 2013 FY | -3.85 Million AUD | 0.0% |
| 2013 Q2 | -572 Thousand AUD | 0.0% |
| 2013 Q1 | -572 Thousand AUD | 0.0% |
| 2013 Q4 | -1.35 Million AUD | 0.0% |
| 2012 FY | - AUD | 0.0% |
| 2011 FY | - AUD | -100.0% |
| 2010 FY | 4.64 Million AUD | -7.1% |
| 2009 FY | 5 Million AUD | 119.98% |
| 2008 FY | 2.27 Million AUD | 140.89% |
| 2007 FY | 944.16 Thousand AUD | 445.86% |
| 2006 FY | 172.96 Thousand AUD | -59.74% |
| 2005 FY | 429.66 Thousand AUD | -69.3% |
| 2004 FY | 1.39 Million AUD | -50.64% |
| 2003 FY | 2.83 Million AUD | 33.68% |
| 2002 FY | 2.12 Million AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 9.61 Million USD | -2034.96% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 165242.333% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | -72.274% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 64321.128% |
| Qrons Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 425287.012% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 8413015.129% |
| BioStem Technologies, Inc. | 15.42 Million USD | -1230.263% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -116116.017% |
| CSL Limited | 7.56 Billion USD | 97.286% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 895.376% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -1652.87% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -145943.416% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -1268.031% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -6614696.905% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -1995.068% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -312082.023% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 600952.123% |
| Mesoblast Limited | -35.16 Million USD | 683.459% |
| Marizyme, Inc. | 457.7 Thousand USD | -44730.698% |
| Genus plc | 178.7 Million USD | -14.824% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 6.775% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -329651.229% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -49926.453% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 1865472.727% |
| ContraFect Corporation | -154 Thousand USD | 133340.909% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 410482.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -267211.525% |
| IMV Inc. | -962.29 Thousand USD | 21423.021% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 53052.379% |
| MultiCell Technologies, Inc. | 49.32 USD | -416040045.985% |
| ONE Bio Corp. | 20.12 Million USD | -919.56% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -409.601% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -419513.497% |
| Q BioMed Inc. | -8988.00 USD | 2283043.925% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -626.211% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 1330435.84% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -362.581% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 18074.425% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -293030.0% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 4143698.546% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 210519.935% |
| GB Sciences, Inc. | -624.00 USD | 32883273.077% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 238616.53% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 98649619.231% |
| Enzolytics Inc. | 30.7 Thousand USD | -668100.469% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -42432.538% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 81.489% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 39980.858% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -33135.555% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 49.899% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 2317071.545% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 244814.904% |
| Kadimastem Ltd | -630.13 Thousand USD | 32662.867% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -20668.719% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 1733864.259% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -116116.017% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -15019.335% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 707655.172% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -45493.643% |
| SYBLEU INC | 11.69 Thousand USD | -1754269.015% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -4352.93% |
| Bioxytran, Inc. | -8285.00 USD | 2476756.608% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 55110.992% |
| Neutra Corp. | 14.33 Thousand USD | -1431298.675% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 250332.927% |
| PureTech Health plc | -1.6 Million USD | 12900.437% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 20593.77% |
| IXICO plc | 3.27 Million USD | -6174.954% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 29666.427% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 11556.784% |
| CSL Limited | 7.7 Billion USD | 97.337% |
| Cellectis S.A. | 18 Thousand USD | -1139850.0% |